KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Deferred Tax Assets: 2009

  • Halozyme Therapeutics' Current Deferred Tax Assets was N/A to -$75,085.0 billion in Q4 2009 from the same period last year, while for Dec 2009 it was -$75,085.0 billion, marking a year-over-year change of. This contributed to the annual value of -$75,085.0 billion for FY2009, which is N/A change from last year.
  • According to the latest figures from Q4 2009, Halozyme Therapeutics' Current Deferred Tax Assets is -$75,085.0 billion.
  • In the past 5 years, Halozyme Therapeutics' Current Deferred Tax Assets registered a high of -$75,085.0 billion during Q4 2009, and its lowest value of -$75,085.0 billion during Q4 2009.
  • Over the past 1 years, Halozyme Therapeutics' median Current Deferred Tax Assets value was -$75,085.0 billion (recorded in 2009), while the average stood at -$75,085.0 billion.